BioCentury | Oct 9, 2006
Clinical News

INNO-105: Development discontinued

...effects. Innovive Pharmaceuticals Inc. , New York, N.Y. Product: INNO-105 Business: Cancer Molecular target: Opioid growth factor receptor (OGFR...
BioCentury | Dec 5, 2005
Clinical News

INNO-105: Phase I started

...patients. Innovive Pharmaceuticals Inc. , New York, N.Y. Product: INNO-105 Business: Cancer Molecular target: Opioid growth factor receptor (OGFR...
BioCentury | Oct 10, 2005
Clinical News

INNO-105: Start Phase I

...patients. Innovive Pharmaceuticals Inc. , New York, N.Y. Product: INNO-105 Business: Cancer Molecular target: Opioid growth factor receptor (OGFR...
Items per page:
1 - 3 of 3